论文部分内容阅读
就病理进程而言,肝细胞癌(hepatocellular carcinoma,HCC)是慢性嗜肝病毒感染过程的延续。中国大陆地区80%的HCC具有乙型肝炎(乙肝)病毒(hepatitis B virus,HBV)感染背景,80%是基于肝硬化背景发生的。针对HBV携带者、慢性乙型肝炎(chronic hepatitis B,CHB)和HBV相关性肝硬化患者不同的疾病阶段应采取不同的监测或筛查策略。临床诊断成立的HBV相关性HCC患者在治疗方案设计应注意3个原则:(1)积极清除实体肿瘤;(2)通过抗病毒等内科手段积极改善肝脏微环境,减少HCC的复发;(3)改善肝脏功能与全身机能状态;减少终末期肝病事件的发生。本研究就
In terms of the pathological process, hepatocellular carcinoma (HCC) is a continuation of the process of chronic hepadnavirus infection. Eighty percent of HCCs in mainland China have a background of hepatitis B virus (HBV) infection, and 80% are based on the cirrhosis background. Different surveillance or screening strategies should be taken for different carriers of HBV carriers, chronic hepatitis B (CHB) and HBV-related cirrhosis. The clinical diagnosis of HBV-related HCC patients should pay attention to three principles in the design of treatment options: (1) the active removal of solid tumors; (2) through the anti-virus and other medical means to actively improve the liver microenvironment and reduce the recurrence of HCC; (3) Improve liver function and general functional status; reduce the incidence of end-stage liver disease. This research is about